Recent advances have highlighted the ability of hematopoietic stem and progenitor cells in the bone marrow to sense peripheral inflammation or infection and adapt through increased proliferation and skewing toward the myeloid lineage. Such adaptations can meet the increased demand for innate immune cells and can be beneficial in response to infection or myeloablation. However, the inflammation-induced adaptation of hematopoietic and myeloid progenitor cells toward enhanced myelopoiesis might also perpetuate inflammation in chronic inflammatory or cardio-metabolic diseases by generating a feed-forward loop between inflammation-adapted hematopoietic progenitor cells and the inflammatory disorder. Sustained adaptive responses of progenitor cells in the bone marrow can also contribute to trained immunity, a non-specific memory of earlier encounters that in turn facilitates the heightened response of these cells, as well as that of their progeny, to future challenges. Here we discuss the mechanisms that govern the adaptation of hematopoietic progenitor cells to inflammation and its sequelae in the pathogenesis of human disease.
H ematopoietic stem cells (HSCs) and hematopoietic progenitor cells in the bone marrow (BM) are responsible for the maintenance of steady-state and stress-adapted hematopoiesis [1] [2] [3] . HSCs (also called 'long-term HSCs' (LT-HSCs)) reside at the top of the hematopoietic hierarchy, have self-renewal and multilineage differentiation ability and give rise to all mature blood cells. LT-HSCs can differentiate into short-term HSCs (ST-HSCs) and multi-potent progenitors (MPPs), which are cells with relatively restricted differentiation potential; LT-HSCs, ST-HSCs and MPPs are collectively known as 'hematopoietic stem and progenitor cells' (HSPCs) 1, 4 . HSPCs are enriched among the Lin 
c-Kit
+ population, wherein LT-HSCs and MPPs can be distinguished via distinct markers, such as markers of the SLAM family of receptors 1, 4 . MPPs differentiate into oligo-potent or uni-potent progenitor cells, such as common myeloid progenitors (CMPs), granulocyte-monocyte progenitors (GMPs) and others, which give rise to mature blood cells 2, 3 . The maintenance of HSCs is facilitated by the highly specialized niche micro-environment, which comprises various cell types, such as mesenchymal stromal cells (MSCs), endothelial cells and megakaryocytes 5 . The HSC niche fosters a variety of juxtracrine interactions (cell-cell or cell-matrix) and paracrine interactions (via cytokines, chemokines or growth factors) involving the HSCs and thereby regulates the self-renewal of HSCs and instructs the differentiation of hematopoietic progenitor cells 5, 6 . As an adaptation to the hypoxic niche micro-environment, HSCs preferentially engage in aerobic glycolysis rather than oxidative phosphorylation for energy production; consistent with that, the glycolytic metabolism of HSCs promotes the maintenance of their stemness 7 . The traditional tree-like hierarchical model of hematopoiesis 1 , in which lineage decisions take place at the MPP stage, is constantly being redrawn. The use of new technologies, such as single-cell analysis [8] [9] [10] [11] [12] , has resulted in alternative models of hematopoiesis that suggest greater functional heterogeneity of HSCs (reviewed in ref. 3 ). Additionally, several surface markers have been identified for the characterization of lineage-biased HSCs and MPPs 13, 14 . 
CD150
-MPPs (MPP4 cells)) 14 . Another example of this is the identification of CD41 as a marker of myeloidbiased HSCs 13 . Moreover, HSC clones primed for the generation of megakaryocytes and platelets have been also reported 8, 9 . In both humans and mice, early lineage priming of HSCs is controlled by distinct gene-expression modules that are regulated by lineage-specific transcription factors 11, 15 . For example, the C/ EBP family of transcription factors and PU.1 regulate entry into the myeloid lineage [15] [16] [17] . As outlined below in greater detail, activation of such lineage-specific transcription factors is also critical for the adaptation of hematopoietic progenitor cells to inflammatory stimuli 18 . Further differentiation decisions in myelopoiesis, a process that leads to the generation of specific myeloid-cell subsets, granulocytes, monocytes and dendritic cells 19, 20 , occur at the level of myeloid progenitor cells 21 and are fine-tuned by additional transcription factors and epigenetic mechanisms [22] [23] [24] . Although it is debated whether HSCs contribute to unperturbed hematopoiesis 25, 26 , HSCs are critical for the reconstitution of hematopoiesis after myeloablation. In this setting, activation of HSCs results in enhanced myelopoiesis at the expense of lymphopoiesis 25 . After transplantation-associated hematopoietic stress, HSCs can bypass several steps of the traditional tree-like hematopoietic hierarchy via direct differentiation into myeloid progenitor cells through asymmetric division 12 ; the latter is a process that gives rise to progeny cells with distinct fates, such as a stem cell and a lineage-committed cell. Hence, upon demand (such as after myeloablation or inflammation), HSCs rapidly respond to replenish myeloid cells through a process called 'emergency myelopoiesis' 20 . Furthermore, the rapid adaptation of hematopoietic progenitor cells to severe bacterial infection that leads to peripheral blood neutrophilia is called 'emergency granulopoiesis' 2 . Although they meet the increased demand for the generation of immune cells,
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NatuRe ImmuNology such adaptations of hematopoietic progenitor cells may contribute to the chronicity of inflammatory diseases 27 . Here we review emerging evidence that the adaptation of hematopoietic progenitor cells to inflammation acts as a central hub of the host response to infectious and inflammatory challenges.
adaptation of HSPCs to inflammation
Similar to the mature immune cells and committed myeloid progenitor cells in the BM, HSPCs can also become directly responsive to acute infection or chronic inflammatory conditions 1, 2, 27 . This HSPC adaptation is tightly orchestrated by a combination of cell-intrinsic mechanisms (transcriptional, epigenetic and metabolic) and cell-extrinsic mechanisms (soluble growth factors, cytokines, microbial ligands and adhesive interactions) 2, 28 . HSPCs are more sensitive to exogenous stimuli than traditionally thought, owing to their expression of receptors for microbial products, such as the Toll-like receptors (TLRs), and receptors for inflammatory cytokines and growth factors such as IL-1β, IL-6, M-CSF and type I and type II interferons, the abundance of which increases massively after systemic infection, thereby enabling HSPCs to sense a systemic infectious or inflammatory challenge directly or indirectly 1, 2 . While such HSPC responses can be beneficial in promoting the elimination of an infection, they may also cause impairment of HSPC function and exhaustion if HSPC activation is chronically sustained 2 , or they may contribute to the chronicity of inflammatory pathologies 27 . The underlying mechanisms and functional outcomes of the adaptation of HSPCs to inflammatory stimuli have only now begun to be understood. Below we discuss the complex regulatory interactions at the interface between inflammation and HSCs.
effects of Tlr signaling on the regulation of myelopoiesis
The seminal observation that hematopoietic progenitor cells express TLRs and that TLR ligation induces myeloid differentiation in a manner dependent on the adaptor MyD88 provided new insight into the role of HSPCs in host defense against pathogens 29 . Subsequent studies have identified indirect, cytokine-mediated and direct effects of TLR ligands on HSPCs (Fig. 1) . After activation of TLRs, ST-HSCs and MPPs produce substantial amounts of cytokines in an manner dependent on the transcription factor NF-κB 30 . Those cytokines, particularly IL-6, can promote, in a paracrine fashion, the proliferation and myeloid differentiation of HSPCs 30 . Additionally, systemic administration of LPS stimulates enhanced HSC proliferation 31 , while chronic treatment with a low dose of LPS results in expansion of HSCs and their myeloid skewing in a cell-intrinsic, TLR4-dependent manner, as shown in BM-chimera experiments with cells from TLR4-deficient mice and TLR4-sufficient mice 32 . However, chronic administration of a low dose of LPS to mice induces functional impairment of HSCs and loss of quiescence, as shown by their reduced repopulation capacity in serial-transplantation experiments 33 . Moreover, a high dose of LPS results in increased death of BM cells and dysfunction of HSCs, despite their initial expansion 34 . Hence, activation of TLR4 on HSCs stimulates their proliferation but may have various detrimental effects on their function due to the proliferative stress in HSCs after ligation of TLR4 33, 35 . Specifically, activation of TLR4 stimulates the proliferation of dormant HSCs while diminishing their self-renewal and repopulation capacity 36 . Those effects are mediated by signaling dependent on the adaptor TRIF and subsequent downstream production of reactive oxygen species (ROS) and activation of the mitogen-activated protein kinase p38, which leads to replication stress and activation of the DNA-repair machinery 36 . Scavenging of ROS or blockade of p38 prevents this endotoxemia-related HSC exhaustion 36 . Consistent with that, TRIF mediates the expansion and functional exhaustion of HSPCs in sepsis 35 .
Different TLR ligands may lead to different emergency myelopoiesis responses by engaging distinct pathways that lead to the generation of Ly6C hi monocytes 37 . Specifically, stimulation of TLR4 by LPS causes an increase in neutrophils and neutrophil-like monocytes derived from GMPs, while stimulation of TLR9 by CpG results in the expansion of dendritic cells and of a functionally distinct monocyte subtype derived from monocyte-dendritic cell progenitors 37 .
Beyond the direct effects of TLR agonists on hematopoietic progenitor cells, endotoxemia also induces the production of myeloid-lineage growth factors (discussed in detail below) and thereby supports the replenishment of blood neutrophils 38 . Notably, the TLR4-MyD88 signaling pathway also mediates LPS-related emergency granulopoiesis through a paracrine pathway, which does not involve direct effects on HSPCs but requires production of the growth factor G-CSF by endothelial cells 38 ( Fig. 1) , as discussed below. . LPS also stimulates the release of cytokines, such as IL-6, from MPPs; IL-6 acts in a paracrine manner to promote HSC proliferation and enhanced myelopoiesis 30 . In parallel, LPS stimulates the release of G-CSF from endothelial cells 38 . G-CSF acts on myeloid progenitor cells, especially GMPs, which drives their differentiation into granulocytes. During the course of infection, M-CSF can act directly on HSCs and promote their myeloid differentiation 53 and on GMPs to promote the generation of monocytes 51 . IFN-α, produced in response to viral infection, induces the entry of HSCs into the cell cycle at the expense of their self-renewal potential 55 . IFN-γ produced during the course of mycobacterial infection results in HSC proliferation and their 'instruction' toward the myeloid lineage 64 . Release of IL-1 during infection or inflammation drives the proliferation and myeloid differentiation of HSCs 18 . Trained immunity induced by β-glucan drives the proliferation and sustained myeloid bias of HSCs via IL-1 and GM-CSF. Trained immunity mediates a beneficial response of HSCs to secondary challenges such as chemotherapy or LPS administration 98 . Additionally, trained immunity induced by BCG reprograms HSCs, which results in the generation of macrophages with enhanced anti-mycobacterial properties 68 .
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Review ARticle | FOCUS NatuRe ImmuNology effect of growth factors on the regulation of myelopoiesis G-CSF serves as a major driver of granulopoiesis under both steadystate conditions and emergency conditions, such as infection, by regulating the expression of myeloid lineage-specific transcription factors and of receptors for myeloid lineage-specific growth factors 2, 39 . Other growth factors that contribute to emergency myelopoiesis are M-CSF and GM-CSF 2 . However, mice deficient in these factors (G-MCF, GM-CSF and M-CSF) can still generate modest numbers of myeloid cells, at least in response to sterile peritoneal inflammation, which highlights a functional redundancy in myelopoiesis 40 . GM-CSF may act alone or together with other cytokines, such as IL-3, in the regulation of myelopoiesis, specifically during chronic inflammation or bacterial infection 2, 41 . During emergency granulopoiesis, G-CSF induces proliferative and lineage-specification signals by acting mainly on CMPs and GMPs, which expand and form well-defined clusters that differentiate into granulocytes 39, 42, 43 . Beyond affecting the differentiation of myeloid progenitor cells, G-CSF may also induce the proliferation of HSCs 44 . Moreover, G-CSF stimulates the mobilization of HSCs from the BM in an indirect fashion, by acting on monocytes in the HSC niche 45, 46 . G-CSF-induced activation of its receptor, G-CSFR, leads to signaling through the transcription factor STAT3, which directly stimulates expression of the master transcriptional regulator of emergency granulopoiesis, C/EBPβ 39, 42 ; in contrast, C/EBPα is the main driver of steady-state granulopoiesis 2 . The effects of STAT3 are counteracted by the regulator of cytokine signal transduction SOCS3, which downregulates G-CSF-induced emergency granulopoiesis; indeed, hematopoietic cell-specific deficiency in SOCS3 results in sustained G-CSF-induced activation of STAT3, enhanced neutrophilia and mobilization of hematopoietic progenitor cells 47 . Consistent with that, the epigenetic modifier TET2, which is mutant in patients with myeloid malignancies 48 , promotes infection-induced emergency myelopoiesis by suppressing the expression of SOCS3 49 . The generation of monocytes in the BM occurs in a manner dependent on the receptor CSFR1, which binds M-CSF 50 . M-CSF acts directly on hematopoietic and myeloid progenitor cells and induces their differentiation into monocytes (Fig. 1) . In vitro treatment of GMPs with M-CSF promotes their differentiation into mature monocytes 51 . The M-CSF-instructed monocyte lineage choice in GMPs is mediated by signaling via the Src family of kinases 52 . M-CSF can instruct myeloid lineage identity in single HSCs, independently of HSC survival or proliferation, by inducing a PU.1-dependent molecular signature 53 . This mechanism of M-CSF-dependent myelopoiesis may provide protection against opportunistic infections after HSC transplantation 54 .
effect of interferons on HSC fate decisions
Type I interferons, especially IFN-α, and the type II interferon (IFN-γ) are central cytokines in the adaptation of HSPCs to inflammation. The type I interferon inducer poly(I:C) (polyinosinic:polycytidylic acid), or IFN-α itself, can drive the proliferation of dormant HSCs ( Fig. 1 ) through a pathway dependent on the IFN-α and IFN-β receptor IFNAR and STAT1; however, chronic administration of IFN-α results in impaired HSC-repopulation capacity 55 . The transcription factor Irf2, a negative regulator of type I interferon signaling, counteracts the effects of type I interferons on HSCs and protects quiescent HSCs from type I interferon-induced, proliferation-associated exhaustion 56 . This type I interferon-dependent functional impairment and attrition of HSCs is due to the induction of DNA damage in HSCs entering the cell cycle, which is associated with enhanced mitochondrial membrane potential and mitochondrial production of ROS 57 . However, type I interferon-triggered proliferation of HSCs may be brief, due to a transient reduction in the expression of genes (such as Cdkn1b, Cdkn1c, Foxo1, Foxo3a or Pten) encoding molecules that enforce quiescence, while reestablishment of HSC quiescence can protect the cells from the pro-apoptotic effects of IFN-α 58 . Hematopoietic cells may engage additional homeostatic protective mechanisms against IFN-α-induced dysfunction. For example, all-trans retinoic acid-induced signaling protects dormant HSCs against poly(I:C)-induced replicative stress 59 . The cyclic GMP-AMP synthase cGAS is an intracellular sensor of pathogen-derived DNA, mostly from viruses. After binding DNA, cGAS generates cyclic GMP-AMP, which -together with the adaptor STING -stimulates the production of type I interferons 60 . Interestingly, the nucleus of LT-HSCs is considerably enriched for cia-cGAS, a circular RNA that antagonizes cGAS's synthase activity and promotes maintenance of LT-HSC dormancy by protecting HSCs against exhaustion mediated by cGAS and type I interferons 61 . The complexity of the effects of IFN-α on the BM is further exemplified by the observations that acute IFN-α-mediated inflammation acts on HSC-niche endothelial cells, affecting vascularity and vessel leakage in the BM 62 , whereas type I interferons can additionally stimulate proliferation and post-transcriptional protein synthesis in a primed subpopulation of stem cell-like megakaryocyte-committed progenitor cells that phenotypically reside among the HSCs, a process that leads to rapid platelet replenishment during acute inflammation 63 . IFN-γ also modulates the maintenance and proliferation of HSCs. Infection with Mycobacterium avium triggers the proliferation of HSCs in an IFN-γ-dependent manner, rather than an IFN-α-dependent manner 64 ( Fig. 1) . Consistent with that, HSC proliferation is abolished in mice with genetic deficiency in either the receptor for IFN-γ or its downstream signal transducer STAT1 64 , which suggests that IFN-γ stimulates entry of HSCs into the cell cycle 64 . However, the effects of IFN-γ on HSCs are context dependent, as IFN-γ inhibits the proliferation of HSCs, impairs their maintenance and negatively affects their recovery during infection with lymphocytic choriomeningitis virus 65 . In the context of such infection, IFN-γ induces myeloid differentiation by acting either directly on myeloid-biased HSC 66 or indirectly; specifically, IFN-γ from cytotoxic T cells stimulates a paracrine pathway that leads to enhanced production of IL-6 by MSCs in the BM, which results in heightened proliferation of MPPs and stimulation of myelopoiesis 67 . Additionally, IFN-γ is responsible for the attrition of HSCs due to their differentiation into myeloid cells and loss of their selfrenewal capacity during chronic mycobacterial infection in mice 66 . Furthermore, intravenously administered mycobacterial bacillus Calmette-Guérin (BCG) triggers the IFN-γ-dependent expansion of HSPCs and their myeloid differentiation through a myelopoiesisrelated transcriptional program 68 ( Fig. 1) .
effects of Il-1β and other cytokines on HSC fate decisions
IL-1β, a central mediator in innate immunity 69 , acts directly on HSCs in vitro, promoting their proliferation and myeloid differentiation through activation of the transcription factor PU.1 18 (Fig. 1) . Administration of IL-1β to mice results in increased numbers of myeloid-biased HSPCs, while BM recovery after chemotherapeutic injury is delayed in IL-1 receptor-deficient mice 18 . Chronic administration of IL-1β diminishes the self-renewal capacity of HSCs, although this effect is reversed after withdrawal of IL-1β 18 . IL-1β, in fact, may account for the hematological abnormalities in patients with X-linked chronic granulomatous disease (X-CGD) and in the respective mouse model, both of which are characterized by IL-1β-associated hyperinflammation 70 . Patients with X-CGD have decreased HSC counts, whereas mice with targeted disruption of the X-linked gene encoding gp91 phox have increased HSC proliferation and impaired reconstitution capacity, as well as boosted myelopoiesis, as assessed by their enhanced number of GMPs 70 . An antagonist of the IL-1 receptor partially restores hematopoiesis in mice with X-CGD 70 , which suggests that IL-1 signaling is responsible in part for this phenotype. Short-term administration 71, 72 and protects mice with cyclophosphamide-induced neutropenia against sepsis 72 , which indicates that timing and dose may be critical regulators of the beneficial or detrimental effects of IL-1 on HSCs. While IL-1 may promote restoration of myelopoiesis, persistent IL-1-mediated inflammation negatively affects HSC functionality.
The cytokine TNF (tumor-necrosis factor) induces proliferation and instructs myeloid-lineage decisions in HSCs and may thus compromise their repopulation capacity 73 . TNF directly upregulates PU.1 in vitro and mediates its activation in mice treated with LPS, because PU.1 is not affected by LPS in TNFdeficient mice 74 . IL-3 derived from B cells of the 'innate response activator' subset amplifies myelopoiesis and inflammation in sepsis. Specifically, the expansion of HSPCs and myeloid progenitor cells is hindered by IL-3 deficiency in mouse sepsis, while high concentrations of IL-3 in plasma correlate with greater mortality in human sepsis 75 . IL-6 regulates the proliferation and differentiation of HSPCs during emergency myelopoiesis 2, 30 . In this context, IL-6 may be derived either from the HSPCs following TLR stimulation 30 ( Fig. 1) or from BM-MSCs after stimulation with cytotoxic T cell-derived IFN-γ 67 . IL-6, via activation of signaling though the tyrosine phosphatase SHP2 and STAT3, can also support survival of TET2-deficient HSPCs and myeloid cells 76 ; as mutations in the gene encoding TET2 are linked with clonal hematopoiesis and a higher risk for the development of leukemia, these observations may indicate how inflammation might promote the survival of pre-leukemic HSPCs 76 . IL-27, a member of the IL-6-IL-12 cytokine family, also acts on HSPCs and promotes emergency myelopoiesis 77 . In a model of malarial infection, deletion of the cytokine receptor IL-27R subunit WSX-1 suppressed the expansion of progenitor cells and their differentiation into myeloid cells, which resulted in increased parasitemia 77 .
Modulation of HSPC adaptation by the BM niche
Emergency myelopoiesis is also regulated by the HSC niche micro-environment in the BM. The niche modulates HSC quiescence, self-renewal, proliferation and differentiation into committed progenitor cells 5, 28, 78, 79 (Fig. 2) . Niche cells such as endothelial cells, nestin-positive MSCs, perivascular stromal cells (including chemokine CXCL12-abundant reticular (CAR) cells) and osteolineage cells regulate HSC function through paracrine signals (growth factors or chemokines) or through adhesive interactions that may also involve extracellular matrix proteins 5, 28, 78, 79 . DEL-1, an adhesive protein secreted by niche endothelial cells, CAR cells and osteolineage cells in the BM, interacts with the integrin β 3 on HSCs and enhances the proliferation of LT-HSCs and their myeloid differentiation, predominantly in the context of LPS-or G-CSF-induced stress myelopoiesis 80 . Another matrixassociated protein, osteopontin, restrains emergency myelopoiesis in favor of lymphopoiesis through a dual mechanism mediated by two distinct isoforms: intracellular osteopontin is pro-apoptotic in myeloid progenitor cells, whereas secreted osteopontin is anti-apoptotic in differentiated lymphoid cells 81 . Furthermore, BM innervation and sympathoadrenergic activity are important regulators of the HSC niche and control the circadian release of HSCs into the circulation; conversely, loss of sympathoadrenergic nerves promotes aging of the niche and impairs the regeneration of hematopoiesis [82] [83] [84] . The progeny of HSCs in the BM may be important mediators for the adaptation of HSPCs to inflammatory signals. Cells of the monocytic lineage are a major cellular target of G-CSF-induced egress of HSPCs from the BM niche and emergency granulopoiesis 46 . G-CSF-induced mobilization of HSPCs is linked to depletion of trophic endosteal macrophages in the BM 85 . CD169
+ macrophages in the BM may interact with osteoblasts or nestin-positive cells in the niche to control the expression of trophic factors such as angiopoietin-1, CXCL12 and c-Kit ligand on HSCs and retention of HSPCs in the niche 85, 86 . Consistent with that, depletion of BM macrophages is sufficient to induce HSPC mobilization 85 . α-SMA + monocytes and macrophages may protect HSPCs from exhaustion in stress conditions such as sublethal irradiation, in part because prostaglandin E 2 produced from these macrophages upregulates CXCL12 in nestin-positive stromal cells, which is critical for stemcell quiescence 87 . BM macrophages can also regulate the HSC niche through the phagocytosis of apoptotic cells (known as 'efferocytosis'). Senescent neutrophils in the circulation upregulate their expression of the chemokine receptor CXCR4 and home back to the BM, where they undergo efferocytosis by BM-resident CD169 + macrophages, a process that in turn promotes the circadian egress of hematopoietic progenitor cells into the circulation 88 (Fig. 2 ). Neutrophils and their precursors in the BM also contribute to demand-adapted myelopoiesis. In response to systemic inflammation, Gr1
+ myeloid cells in the BM release ROS, which stimulates the proliferation and differentiation of myeloid progenitor cells and thus enhances myeloid-cell output 89 . Granulocyte-derived TNF promotes vessel growth and thereby promotes HSPC regeneration 90 . Megakaryocytes regulate HSC quiescence through the cytokine TGFβ1 or CXCL4 and may promote post-injury regeneration of HSCs through the growth factor FGF-1 91, 92 . Megakaryocytes preferentially regulate the proliferation of vWF + platelet-and myeloidbiased HSCs 93 . In vivo high-resolution imaging has revealed the co-localization of HSPCs with CD4
FoxP3
+ regulatory T cells (T reg cells) that accumulate on the endosteal BM niche 94 . These T reg cells may confer immune privilege to the HSPC niche and thus prevent the allogeneic rejection of transplanted HSPCs or protect endogenous HSPCs from excessive inflammation. In support of that notion, a niche-specific subpopulation of CD150 hi T reg cells promotes HSC quiescence and engraftment of HSCs through a mechanism dependent on adenosine generated by the ectoenzyme CD39, which protects HSCs from oxidative stress 95 (Fig. 2) . Together, various cells in the HSC niche contribute to the context-dependent adaptation of HSPCs to diverse inflammatory challenges.
The effect of trained immunity on HSPCs
Trained immunity is a form of adaptation that enhances the response of innate immune cells to secondary challenges independently of adaptive immunity 96, 97 . Trained immunity can be triggered by certain microbial components, such as the fungal cell-wall constituent β-glucan or vaccines like BCG, and involves immunometabolic and epigenetic alterations in target cells 96, 97 . Trained innate immunity operates in hematopoietic progenitor cells 68, 98 , which resolves a historic paradox about the long-term effect of trained immunity on myeloid cells with a relatively short lifespan. Trained immunity induced by the injection of β-glucan into mice leads to the expansion of myeloid-biased HSPCs, such as CD41 + LT-HSCs and MPP3 cells, in the BM 98 . β-glucan-induced myelopoiesis requires signaling through IL-1β and is associated with enhanced glycolysis and cholesterol biosynthesis in HSPCs. Increased amounts of cholesterol in HSPCs from 'β-glucan-trained' mice results in enhanced signaling via CD131, the common β-subunit of the receptor for IL-3 and GM-CSF (IL-3Rβ), in LT-HSCs and MPPs 98 . Consistent with that, elevated expression of IL-3Rβ and enhanced myeloid bias are observed in HSPCs after blockade of cholesterol efflux 99 . Notably, β-glucan-induced training of HSPCs and enhancement of myelopoiesis confers a favorable outcome onto secondary systemic challenge with LPS and protection against chemotherapyinduced myelosuppression 98 ( Fig. 1) . The administration of BCG to mice also stimulates the expansion of HSPCs and promotes myelopoiesis in a manner that requires IFN-γ signaling. Notably, macrophages derived from 'BCG-trained' progenitor cells mediate host protection against infection with Mycobacterium tuberculosis Fig. 1) . Hence, trained innate immunity in hematopoietic progenitor cells 68, 98 shares common features with emergency myelopoiesis in response to systemic infection or inflammation 2 . HSC expansion due to inflammatory stimuli such as LPS or IFN-α leads to exhaustion of HSCs, which is associated with compromised self-renewal and capacity for competitive repopulation and is mediated by DNA damage associated with replication str ess 35, 36, 57, 100 . Interestingly, β-glucan-triggered training of HSPCs is associated with attenuated LPS-or chemotherapy-induced replication stress in HSCs 98 . The beneficial effect of trained immunity in this case may lie in changes in cellular metabolism. While mitochondrial ROS and activation of oxidative phosphorylation are associated with DNA damage in HSCs and lead to functional impairment of these cells, the maintenance of LT-HSCs depends on glycolysis 7, 57, 101, 102 . HSPCs in β-glucan-trained mice retain a glycolytic signature even after chemotherapy, which may be linked with resistance to replication stress-related DNA damage 98 . This could suggest that certain agonists of trained immunity may act favorably on HSCs and myelopoiesis by counteracting inflammation-dependent stress and impaired function of HSCs 98 . Genetic targeting of the pathways linked to trained immunity, such as IL-1 signaling or cell metabolism in hematopoietic progenitor cells, mature myeloid cells and components of the HSC niche, is needed to clarify the mechanisms that underlie the modulation of myelopoiesis by trained immunity.
adaptation of HSPCs in inflammatory diseases
There is increasing evidence that chronic metabolic inflammatory conditions, such as obesity and diabetes, or cardiovascular inflammatory conditions, such as atherosclerosis, can alter hematopoiesis. Reciprocally, adaptation of hematopoietic progenitor cells that leads to chronic leukocytosis may contribute to the perpetuation and chronicity of such disorders 27, 103, 104 (Fig. 3) . Diabetes-associated hyperglycemia and obesity result in monocytosis and neutrophilia in mice 105, 106 . In hyperglycemia, the neutrophil-derived damageassociated molecular pattern S100A8/A9 interacts with the receptor RAGE on CMPs and triggers the production of M-CSF and GM-CSF, which stimulate the proliferation of GMPs and, in turn, monocytosis, neutrophilia and atherosclerosis 105 . Similarly, genetic or diet-induced obesity in mice stimulates the proliferation of myeloid progenitor cells in the BM, in a manner dependent on the NLRP3 inflammasome-dependent production of IL-1β in adiposetissue macrophages 106 (Fig. 3) . Weight loss in humans after bariatric surgery substantially decreases the number of circulating monocytes and neutrophils 106 . The myeloid bias of HSPCs from mice with diet-induced obesity is maintained after serial transplantation into recipient mice, and the obesity-related myeloid reprogramming is + macrophages in the BM niche interact with osteoblasts or nestin-positive perivascular cells and control their expression of HSC-trophic factors, including CXCL12, which contributes to the retention of HSCs in the niche 85, 86 . CD169
+ macrophages phagocytose apoptotic neutrophils that, after senescence, home back to the BM; this process promotes the circadian egress of hematopoietic progenitor cells into the circulation 88 . α-SMA + macrophages secrete prostaglandin E 2 (PGE2), which acts on nestin-positive (nestin + ) cells that in turn secrete CXCL12 and thereby contribute to the quiescence and retention of HSCs 87 . In response to systemic infection or inflammation, Gr1
+ myeloid cells in the BM release ROS; this stimulates the expansion and differentiation of myeloid progenitor cells and thus contributes to demand-adapted myelopoiesis 89 . Moreover, under inflammatory conditions, granulocytes in the BM can secrete TNF, which stimulates vessel growth and thus indirectly promotes HSPC regeneration 90 . CD4
+
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+ FoxP3 + T reg cells accumulate on the endosteal BM niche and confer immune privilege onto the HSC niche. CD150 hi T reg cells support HSC quiescence and engraftment via ectoenzyme CD39-generated adenosine 95 . Megakaryocytes control HSC quiescence through TGFβ1 or CXCL4 signaling 91, 92 .
Review ARticle | FOCUS . The myeloid-biased reprogramming of HSPCs requires signaling through TLR4, MyD88 and TRIF and contributes to the enhanced generation of proinflammatory macrophages in the adipose tissue; this thereby exacerbates obesity-related adipose-tissue inflammation and dysfunction 107, 108 . Experiments with germ-free mice have also indicated an important role for the gut microbiota in myelopoiesis 109 . In this context, altered gut microbiota in mice due to a high-fat diet promotes HSPC differentiation toward myelopoiesis at the expense of lymphopoiesis through the modulation of niche MSCs 110 . Altered hematopoiesis is also integral to atherosclerosis and cardiovascular disease 27, 103 . Myocardial infarction (MI) results in enhanced myelopoiesis, which may involve several complementary and probably synergistic mechanisms 27 (Fig. 3) . For example, a myeloid-biased subset of HSPCs (CCR2
+ cells) with a greater proliferative and less self-renewal capacity than that of HSCs contributes to the enhanced myelopoiesis after MI 111 . Increased sympathoadrenergic activity causes enhanced mobilization of HSPCs from the BM to the spleen, which becomes a site for increased extramedullary myelopoiesis 112 . Interestingly, enhanced sympathoadrenergic activity mediates the increased stress-induced proliferation of LT-HSCs and myelopoiesis, which probably explains how psychosocial stress promotes atherosclerosis 113 . In a similar context, a disturbed sleep pattern contributes to atherosclerosis by dysregulating a neurological-immunological axis that links hypothalamic hypocretin to the regulation of myelopoiesis 114 . IL-1β is a central player in enhanced myelopoiesis after MI, as it can promote HSPC proliferation in a direct or indirect, niche cell-dependent fashion, and can also stimulate splenic monocytopoiesis 115, 116 . Detrimental effects of trained innate immunity may also contribute to Western diet-associated atherosclerosis 117 . A Western diet induces NLRP3-and IL-1-dependent transcriptomic and epigenetic reprogramming in GMPs in atherosclerosis-prone mice deficient in the low-density lipoprotein receptor Ldlr, which drives the GMPs toward enhanced proliferation and inflammatory responses; consistent with the long-term effects of trained immunity, this reprogramming of progenitor cells is sustained even after mice are switched back to a standard chow diet 117 . Moreover, GM-CSF from the infarcted myocardium stimulates the expansion of myeloid-biased CD131 + MPP3 cells in the BM 118 . Cholesterol biosynthesis and/or mevalonate, the first metabolite of the cholesterol-biosynthetic pathway, are important mediators of trained innate immunity in mature myeloid cells or hematopoietic progenitor cells 98, 119, 120 . The cholesterol-dependent immunometabolic crosstalk during trained immunity may also be intimately linked with the dyslipidemia-or hypercholesterolemia-associated altered hematopoiesis that leads to enhanced myelopoiesis during atherosclerosis 97, 103 . Disrupted cholesterol-efflux pathways and enhanced accumulation of cholesterol in HSPCs drive myelopoiesis in a cell-intrinsic fashion 99, 121 . Major players in the cellular efflux of cholesterol are apolipoprotein E and the ATP-binding cassette transporters ABCA1 and ABCG1 121 . The latter are upregulated in pro-resolving macrophages after efferocytosis dependent on the transcription factor LXR and contribute to inflammationresolution programs 122, 123 . Cholesterol accumulation in HSPCs due to double deficiency in ABCA1 and ABCG1 or due to deficiency in apolipoprotein E results in the expansion and myeloid differentiation of HSPCs and, hence, peripheral monocytosis and neutrophilia 99, 124 . The underlying mechanism involves membrane alterations associated with enhanced intracellular cholesterol and elevated cell-surface expression of lipid raft-associated IL-3Rβ (CD131), which facilitates enhanced IL-3-or GM-CSF-dependent signaling for the induction of myelopoiesis 99, 124 (Fig. 3) . A similar mechanism involving enhanced cholesterol accumulation and lipidomic membrane remodeling that augment CD131-dependent signaling in HSPCs, leading to their myeloid differentiation, operates in β-glucan-induced trained immunity in HSPCs 98 . Together, immunometabolic adaptations of hematopoietic progenitor cells to inflammatory signals may be the common denominator of the modes of action in trained innate immunity and cardio-metabolic disease. In addition, (mal)adaptive training of hematopoietic progenitor cells may provide a mechanistic basis for comorbidities, such as the enhanced risk of cardiovascular complications in patients with rheumatoid arthritis, periodontitis or other autoimmune or inflammatory disorders 125, 126 . Age-associated impairment in HSC function is associated with replication stress 100 , while diminished DNA-damage-response and DNA-damage-repair pathways in aged HSCs may promote the accumulation of mutations that lead to hematological malignancies 127 . Autophagy counteracts the age-associated dysfunction of HSCs by clearing mitochondria and thereby facilitates the maintenance of HSC quiescence and regenerative capacity 128 . Aged HSCs display diminished self-renewal and a myeloid bias [129] [130] [131] . CD61
hi LT-HSCs are highly responsive to inflammatory stimuli and predominate among aged LT-HSCs as a myeloid-biased subset regulated by the transcription factors KLF5, IKZF1 and STAT3 131 . The propensity of aged HSCs to accrue mutations and have a myeloid bias and enhanced responsiveness to inflammation may provide a mechanism for clonal hematopoiesis (also known as 'clonal hematopoiesis of indeterminate potential') 132, 133 , whose prevalence increases considerably with age and is defined by . Moreover, in MI, increased sympathoadrenergic activity (for example, due to pain or anxiety) causes the expansion of HSPCs, including a subset of CCR2 + HSPCs, and their enhanced egress from the BM, which further contributes to enhanced myeloid-cell output 111, 112 . Such enhanced generation of inflammatory myeloid cells may aggravate inflammation and interfere with tissue healing in MI and perhaps in other inflammatory conditions. GM-CSF produced after MI (or during other inflammatory disorders) promotes myelopoiesis by acting on HSPCs or myeloid progenitor cells (MyP) 41, 118 . The accumulation of cholesterol in HSPCs (for example, due to dyslipidemia or hypercholesterolemia) causes membrane changes associated with enhanced IL-3-or GM-CSF-dependent signaling that induces myelopoiesis 99, 124 . Such immunometabolic changes that result in GM-CSF-dependent enhanced myelopoiesis are also associated with trained immunity-induced IL-1β 98 and may explain, at least in part, why trained innate immunity aggravates cardiovascular inflammation [132] [133] [134] . Consistent with that, mouse deficiency in the epigenetic regulator TET2 results in the expansion of HSPCs with myeloid bias, which leads to myeloproliferation 135 . Chimeric Ldlr-deficient mice partially or completely reconstituted with TET2-deficient BM cells have exacerbated atherosclerosis typified by the presence of proinflammatory macrophages with enhanced NLRP3-dependent production of IL-1β 133, 134 . Clonal hematopoiesis may also accelerate heart failure in an IL-1β-dependent manner 136 . The concept of clonal hematopoiesis, therefore, could integrate aging-and inflammation-related adaptations in progenitor cells of the myeloid lineage with cardio-metabolic inflammation. Activation of the NLRP3 inflammasome is linked to clonal HSPC expansion and progression of myelodysplastic syndrome 137 , while IL-6-related inflammation promotes the survival of TET2-deficient HSPCs 76 , which would indicate inflammation as a driver of clonal hematopoiesis and myelodysplastic syndrome.
IL-1β seems to be the common denominator of trained innate immunity in hematopoietic progenitor cells, enhanced myelopoiesis in cardio-metabolic disease and clonal hematopoiesis-related exacerbated vascular inflammation. The success of IL-1β blockade in atherosclerosis (in the CANTOS trial) 138 further supports the proposal of a major role for IL-1β in these conditions. Moreover, inflammation induced by TLR2 agonists or disseminated bacteria resulting from a disrupted intestinal barrier may promote the progression to pre-leukemic myeloproliferation in TET2 deficiency 139 . Further investigations could elucidate the potential links among the aforementioned inflammatory (IL-1β-related) processes, especially trained innate immunity and clonal hematopoiesis, as they seem to participate in a self-sustained vicious cycle wherein inflammatory disease and inflammatory adaptations of hematopoietic progenitor cells engage in reciprocally reinforced interactions.
Conclusions
The ability of hematopoietic progenitor cells to sense and adapt to inflammatory stimuli renders them central players in the context of acute peripheral inflammation or infection 1, 2 . During infection, HSPCs react to TLR ligands, inflammatory cytokines (including IL-1 or interferons) and growth factors. Such inflammatory signaling in HSPCs can drive their expansion and myelopoiesis but may also cause HSPC exhaustion if chronically sustained 2 . With the exception of their role in chronic cardio-metabolic diseases 27, 103 , the role of hematopoietic progenitor cells as central determinants of the host response in chronic diseases has been underappreciated. In cardiometabolic diseases (and possibly other chronic disorders), the adaptation to inflammation that drives myelopoiesis of HSPCs generates a destructive feed-forward loop (Fig. 4) in which increased numbers of inflammatory myeloid cells enhance inflammation, which in turn perpetuates HSPC-mediated myelopoiesis 27, 103, 111, 112, 116, 121 . Notably, previous infectious or inflammatory challenges can epigenetically imprint an 'inflammatory memory' onto hematopoietic progenitor cells 97, 98, 117 and thereby contribute to trained immunity. As trained innate immunity facilitates cardiovascular inflammation 117 , we hypothesize that the development of clonal hematopoiesis, which is associated with greater cardio-metabolic inflammation [132] [133] [134] , might be linked to selective pressure for inflammatory memory [96] [97] [98] . A major question is whether adaptation of hematopoietic progenitor cells to inflammation can provide a unifying concept in which inflammatory stimuli (such as infections) and multiple risk factors (such as obesity, dyslipidemia and psychosocial stress) can be integrated in a meaningful manner for better understanding of the pathogenesis of different forms of chronic inflammatory diseases or even malignant disorders. This challenging concept needs to be addressed by interdisciplinary studies that bring together experts in immunology, hematopoiesis, metabolism and cardiovascular medicine, as well as mathematical modeling, which could potentially lead to new risk-assessment scores for chronic inflammatory diseases. Review ARticle | FOCUS
